Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,257 INR | +1.36% | +2.75% | -0.28% |
Apr. 02 | Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer | CI |
Apr. 02 | Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.82 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.28% | 2.3B | B- | ||
+33.28% | 664B | C+ | ||
+29.29% | 567B | B | ||
-7.16% | 354B | C+ | ||
+19.27% | 330B | B- | ||
+4.74% | 286B | C+ | ||
+13.79% | 234B | B+ | ||
+4.93% | 199B | B- | ||
-9.78% | 196B | A+ | ||
-4.74% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PFIZER Stock
- Ratings Pfizer Limited